The U.S. Supreme Court agreed to consider a pair of whistleblower-initiated False Claims Act cases accusing two pharmacy operators of billing Medicare and Medicaid programs for prescription drugs at artificially high rates while charging non-governmentally insured customers lesser prices for those same drugs.
News & Insights
A jury returned a rare verdict in a "qui tam" False Claims Act matter, finding a pharmaceutical company liable for $61 million in damages arising out of purported misconduct involving the Medicaid Drug Rebate Program.
The U.S. Court of Appeals for the Ninth Circuit affirmed a preliminary injunction sought by the CFTC in a case involving fraud-related charges against a precious metals credit company.
In Axon Enterprise v. Federal Trade Commission, the U.S. Court of Appeals for the Ninth Circuit affirmed the dismissal of an action by Axon Enterprises, Inc., arguing that the FTC's administrative enforcement process violated Axon's constitutional rights.
A direct selling company headquartered in California settled DOJ and SEC charges for violating the Foreign Corrupt Practices Act by bribing Chinese government officials. The company sells health and personal care products in over 90 countries.